BTK and infection: B-cell-targeting therapies, including anti-CD20, anti-CD38 monoclonal antibodies, and Bruton’s tyrosine kinase (BTK) inhibitors, further compromise humoral immunity, exacerbating susceptibility to infections [8,9,10].